CDC Panel to Discuss Hepatitis B Vaccine Scheduling Changes

A federal vaccine advisory panel, recently updated by Health Secretary Robert F. Kennedy Jr., is anticipated to vote on delaying the hepatitis B vaccine typically administered to newborns until they reach age 4. This information comes from two former senior officials at the Centers for Disease Control and Prevention (CDC).

Demetre Daskalakis, a previous director at the National Center for Immunization and Respiratory Diseases, noted that there will likely be discussions aimed at shifting the timing of the hepatitis B vaccine away from birth. He mentioned that this seems to be a priority for the Secretary.

The forthcoming vote is scheduled for Thursday during the next meeting of the CDC’s Advisory Committee on Immunization Practices (ACIP), set for September 18-19 at a CDC office in Atlanta, Georgia.

For over three decades, the CDC has recommended infants receive the first dose of the hepatitis B vaccine at birth. This early vaccination has significantly reduced the disease’s prevalence among American children, leading to a staggering 99 percent drop in case rates for people aged 19 and younger between 1990 and 2022.

Pediatricians, however, express concern that postponing the vaccine until age 4 could result in more infections among children. Dr. Eric Ball from Orange County, California, stated, “Age four makes zero sense… We really should adhere to a universal strategy to safeguard the entire population.”

The panel will also consider recommendations regarding the combined measles, mumps, rubella, and varicella vaccines, as well as COVID-19 vaccines. Concerns have been raised that altering vaccination schedules might restrict access for families, as ACIP recommendations often dictate insurance coverage and federal programs.

Typically, prior to any changes, ACIP conducts thorough data analysis. However, as of late August, the review process for the hepatitis B vaccine had not started, according to Daskalakis and an additional former official who requested anonymity.

“This is quite unusual. There hasn’t been a workgroup to discuss it,” Daskalakis commented.

In response, Health and Human Services spokesman Andrew Nixon assured that any updates to vaccine recommendations would be conducted transparently and based on rigorous scientific evidence.

The draft agenda for the meeting was released to the public just days before it is set to occur, raising eyebrows about the timing. During ACIP’s last meeting in June, chairman Martin Kulldorff, appointed by Kennedy, questioned the necessity of vaccinating every newborn, citing limited transmission methods for the virus.

Kulldorff, who has garnered attention for opposing various public health measures during the COVID-19 pandemic, suggested that delaying vaccination might be justifiable unless the mother is known to be hepatitis B positive.

The CDC advisory panel is still expected to recommend administering the vaccine to newborns whose mothers are at high risk for the disease.

Historic Vaccination Success

In 1991, federal health officials found it advisable for newborns to receive their first dose of the hepatitis B vaccine within 24 hours of birth. This preventive measure blocks the virus’s potential transmission during delivery.

Despite parents having the option to opt out of the vaccine, many schools and daycare facilities mandate proof of hepatitis B vaccination for enrollment.

Altering this recommendation has caused distress among individuals living with the virus. Wendy Lo, 52, from the San Francisco Bay area, expressed her frustration, saying she wouldn’t want anyone to endure the challenges that come with chronic hepatitis B. She learned of her condition only through routine screening during her college years.

Lo credits the vaccines with protecting her family. “If you get vaccinated, we can be together,” she mentioned to her partner, who subsequently received the vaccine.

The CDC estimates that half of those with hepatitis B are unaware of their infection, which can range from mild to severe. Most chronic cases are found among individuals born outside the U.S., especially in the Asian and Pacific Islander communities, followed by Black populations.

Lo was determined to ensure her children received the hepatitis B vaccine at birth, a decision she feels protected them from the virus.

Data suggests that contracting hepatitis B at a younger age increases the risk of developing chronic conditions later in life. Those who become chronic carriers can unknowingly spread the virus to others and face severe long-term health risks.

Treatments for hepatitis B were not available until the 1990s, and Lo’s chronic infection has already adversely affected her liver. She now undergoes regular blood tests with anxiety, fearing the outcomes.

As she apprehensively approaches her 50s, she emphasizes the vaccine’s importance, stating, “The vaccine is safe and effective; it’s life-saving and protects against cancer. How many vaccines do that?”

A Shift in Focus

Initially, public health efforts in the 1980s were directed at high-risk adults, as hepatitis B was perceived mainly as an adult-acquired infection. However, the understanding of the virus has evolved significantly over the years.

As hepatitis B infection rates remained consistently high in the past, it became clear that newborns were a vulnerable group needing protection, leading to the 1991 recommendation for universal vaccination before infants leave the hospital.

Data shows a stark decline in hepatitis B cases among youth, dropping from 3.03 cases per 100,000 in 1990 to below 0.1 per 100,000 in 2022. While often associated with high-risk behavior, the virus can be transmitted in various everyday situations, notably among children.

If the CDC adjusts its recommendations, health insurers might not cover the cost of the vaccine if administered before the new age threshold, shifting financial responsibility onto parents.

Changes could undermine free access to the vaccine through federal programs as soon as the acting CDC director approves any new guidance.

Schaffner, still a liaison member of ACIP, aims to voice his support for universal newborn vaccination at the upcoming meeting, expressing concern for future generations.

“We’re likely to see cases of hepatitis B rise again, impacting the next generation,” he warned, adding that this could lead to a resurgence of the disease, which had been on the decline due to vaccination efforts.